Registry of Comprehensive Imaging and Physiological Evaluation of Deferred Lesions Based on FFR

Active, not recruiting

• Conditions: Ischemic Heart Disease
• Interventions: Device: Comprehensive physiologic evaluation; Device: Intravascular imaging devices

• Registration Number: NCT03030495
• Lead Sponsor: Samsung Medical Center

Brief Summary

1. To compare the risk of atherosclerotic lesion progression and subsequent patient-oriented composite outcomes (all-cause mortality, any MI, or any Ischemia-driven repeat revascularization) between deferred lesions with or without over microvascular disease, defined as physiological classification

2. To explore independent predictors of atherosclerotic lesion progression in deferred lesions based on fractional flow reserve-guided strategy and treated by contemporary medical treatment

Detailed Description

The coronary artery system has 3 components with different functions: conductive epicardial coronary arteries, arterioles, and capillaries. When any one of these systems fails, myocardial ischemia can occur. Therefore, the presence of epicardial coronary artery stenosis is not necessarily a prerequisite for ischemic heart disease (IHD). Although it has not been established that microvascular disease is independent of macrovascular disease, clinical studies have consistently shown that the presence of microvascular disease is an independent predictor of poor clinical outcomes, especially in patients with acute myocardial infarction (MI).

The pressure-derived fractional flow reserve (FFR) index has become a standard invasive method to evaluate the functional significance of epicardial coronary artery stenosis, and clinical outcomes of FFR-guided percutaneous coronary intervention (PCI) have proven to be better than those of angiography-guided PCI or medical treatment. Although FFR-guided PCI has been reported to improve patient outcomes and FFR is now regarded as the gold-standard invasive method to assess the functional significance of coronary artery stenosis, there is still room for further improvement in the diagnosis and treatment of patients with high FFR. In the FAME II study, 14.6% of the registry arm (FFR \> 0.80 and deferral of PCI) experienced persistent angina, and 9.0% of these patients had clinical events during a 2-year follow-up period.

Therefore, microvascular assessment using coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR) can provide additional diagnostic and prognostic insights for IHD patients, especially in those with high FFR.

Recently, Lee et al. (JACC 2016) investigated clinical outcomes among patients with high-FFR and deferred revascularization, according to physiologic classification using CFR and IMR. Lee et al. firstly presented that 7.0% of patients with high FFR had high IMR and low CFR and were regarded as having overt microvascular disease. Although the proportion of patients with high FFR who had overt microvascular disease was small, Group D had the poorest clinical outcomes during follow-up. The presence of overt microvascular disease was an independent prognostic factor in patients with high FFR. In addition, the presence of overt microvascular disease had additive prognostic value aside from clinical risk factors, with significantly improved discriminant function of the prediction model. These results suggest that the invasive physiologic assessment for microvascular disease combined with CFR and IMR can help identify patients at high risk for future cardiovascular events among those with high FFR.

Previous studies have shown that the presence of microvascular disease is associated with a higher risk of cardiovascular events such as cardiac death, MI, or revascularization in patients without flow-limiting epicardial stenosis. Several mechanisms have been proposed for the association of microvascular disease and poor clinical outcomes. In addition to myocardial ischemia, microvascular disease is reported to be associated with endothelial dysfunction and inflammatory activity that precedes intimal thickening, lipid deposition in the macrovascular system, and coronary vasomotor dysfunction. In a study by Dhawan et al., coronary microvascular dysfunction in patients with non-obstructive coronary artery disease was associated with higher serum high-sensitivity C-reactive protein and a higher frequency of thin-cap fibroatheroma.

In the Lee et al.'s study, the higher clinical event rates in patients with overt microvascular disease resulted from cardiac death and revascularization rates higher than those of the other groups. These results imply that the presence of overt microvascular disease can induce accentuated atherosclerotic progression and subsequent clinical events including cardiac death and ischemia-driven repeat revascularization.

Therefore, the IMaging and Physiologic Predictors of Atherosclerotic Progression in Deferred Lesions with Contemporary Medical Treatment based on Fractional Flow Reserve-guided Strategy (IMPACT-FFR registry) was designed to compare the risk of atherosclerotic plaque progression and subsequent clinical events between deferred lesions with or without over microvascular disease, defined as physiological classification and also to explore independent predictors of atherosclerotic lesion progression in deferred lesions based on fractional flow reserve-guided strategy and treated by contemporary medical treatment.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2016-12
• Study First Submitted: 2016-12-20
• Study First Submitted QC: 2017-01-22
• Study First Posted: 2017-01-25
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-19
• Last Update Posted: 2024-04-22
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 1400

Inclusion Criteria

• Subject must be ≥ 18 years
• Patients suspected with ischemic heart disease
• Patients with intermediate degree of stenosis (30-70% stenosis by visual estimation) with fractional flow reserve of >0.80 in major epicardial coronary artery amenable to stent implantation or vessel size≥2.5 mm
• Patients whose coronary stenosis were evaluated by invasive imaging techniques (intravascular ultrasound and optical coherence tomography) and physiologic assessment (coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve)
• Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and he/she or his/her legally authorized representative provides written informed consent to any study related procedure

Read More

Exclusion Criteria

• End-staged renal disease on peritoneal dialysis or hemodialysis (estimated GFR < 15mL/min)
• Acute hepatic injury
• Cardiogenic shock (systolic blood pressure < 90mmHg or requiring inotropics to maintain blood pressure > 90mmHg)
• The patient has a known hypersensitivity or contraindication to any of the following medications: statin, ezetimibe, heparin, aspirin, clopidogrel, prasugrel, ticagrelor
• Non-cardiac co-morbid conditions are present with life expectancy <2 year (per site investigator's medical judgment)
• Unable to perform invasive imaging study (intravascular ultrasound and optical coherence tomography) or physiologic assessment (coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve)

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Overt microvascular disease	Comprehensive physiologic evaluation	Fractional flow reserve\>0.80, coronary flow reserve\<2 \& Index of microvascular resistance\>25U
Overt microvascular disease	Intravascular imaging devices	Fractional flow reserve\>0.80, coronary flow reserve\<2 \& Index of microvascular resistance\>25U
No Overt microvascular disease	Comprehensive physiologic evaluation	Fractional flow reserve\>0.80, coronary flow reserve\>2 \& Index of microvascular resistance\<25U
No Overt microvascular disease	Intravascular imaging devices	Fractional flow reserve\>0.80, coronary flow reserve\>2 \& Index of microvascular resistance\<25U

Primary Outcome Measures

Name	Time	Method
patient-oriented composite outcome	24 months	a composite of all-cause death, MI, any repeat revascularization

Secondary Outcome Measures

Name	Time	Method
Change in Plaque burden at minimum lumen area site	12 months	Change in Plaque burden at minimum lumen area site at 12-month Plaque burden = (EEM-MLA)/EEM x 100
Non-target vessel nonfatal MI	24 months	Non-target vessel nonfatal MI
Seattle Angina Questionnaires	24 months	Angina severity measured with Seattle Angina Questionnaires
Change in Fractional flow reserve	12 months	Change in Fractional flow reserve at 12-month
patient-oriented composite outcome	60 months	a composite of all-cause death, MI, any repeat revascularization
All-cause nonfatal MI	24 months	All-cause nonfatal MI
Change in total atheroma volume index	12 months	Indexed total atheroma volume (TAVi): Σ(EEM CSA -lumen CSA)/plaque length
Change in fibrous cap thickness by OCT	12 months	Change in fibrous cap thickness by OCT at 12-month
cardiac death	24 months	cardiac death
Change in normalized total atheroma volume	12 months	TAVnormalized = \[Σ (EEM CSA - lumen CSA) / no. of images in pullback images in cohort\] X median no. of images in cohort
Change in index of microcirculatory resistance	12 months	Change in index of microcirculatory resistance at 12-month
All-cause death	24 months	All-cause death
Target-vessel nonfatal MI	24 months	Target-vessel nonfatal MI
Change in coronary flow reserve	12 months	Change in coronary flow reserve at 12-month

Trial Locations

Locations (4)

Inje University Ilsan Paik Hospital; 🇰🇷 Goyang-si, Korea, Republic of

Keimyung University Dongsan Medical Center; 🇰🇷 Daegu, Korea, Republic of

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of